Publications by the researcher in collaboration with J. Apperley (4)

2023

  1. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

    Leukemia, Vol. 37, Núm. 3, pp. 617-626

2022

  1. CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S295-S296

2021

  1. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

    Blood, Vol. 138, Núm. 21, pp. 2031-2041

2020

  1. Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors

    Leukemia, Vol. 34, Núm. 6, pp. 1495-1502